FROM
ISSUE 1614
ISSUE 1614
December 28, 2020
Issue 1614
| Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue. |
An EUA for Casirivimab and Imdevimab for COVID-19
December 28, 2020 (Issue: 1614)
The FDA has issued an Emergency Use Authorization
(EUA) for Regeneron's investigational monoclonal
antibodies casirivimab (REGN10933) and imdevimab
(REGN10987) to be administered together by IV
infusion for treatment of mild to moderate COVID-19
in adults and pediatric patients (≥12 years old and
weigh ≥40 kg) who are at high risk of progressing to
severe COVID-19 and/or hospitalization (see Table 1).
Bamlanivimab (LY-CoV555; Lilly), another monoclonal
antibody, received an EUA for the same indication on
November 9, 2020.
... more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this issue? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1614
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian